Transcription factors: Molecular targets for prostate cancer intervention by phytochemicals

Current Cancer Drug Targets

Volumn 7, Issue 4, 2007, Pages 355-367

  Kaur, Manjinder ^a   Agarwal, Rajesh ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Cancer chemoprevention; Phytochemicals; Prostate cancer; Silibinin; Transcription factors

Indexed keywords

3 INDOLEMETHANOL; ANDROGEN RECEPTOR; APIGENIN; BAICALIN; CURCUMIN; EMODIN; EPIGALLOCATECHIN GALLATE; GANODERMA LUCIDUM EXTRACT; GENISTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDIRUBIN; MYC PROTEIN; ORIDONIN; PHYTIC ACID; PLANT MEDICINAL PRODUCT; PROTEIN P53; RESVERATROL; SILIBININ; SILYMARIN; STAT PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR EGR 1; TRANSCRIPTION FACTOR ETS 2; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR SP; TRANSCRIPTION FACTOR SP1; UNINDEXED DRUG;

CANCER CELL; CANCER GROWTH; CANCER INCIDENCE; CANCER THERAPY; CELL SURVIVAL; CYTOLOGY; CYTOTOXICITY; DIET; GENE EXPRESSION; HUMAN; NONHUMAN; PROSTATE CARCINOMA; PSYCHOTRAUMA; REVIEW; SUPPLEMENTATION;

ANTICARCINOGENIC AGENTS; HUMANS; MALE; PLANTS; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 34249798732     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800907780809732     Document Type: Review

References (220)

1. Scher, H. I.; Chung, L. W. Bone metastases: improving the therapeutic index. Semin. Oncol. 1994, 21, 630-656.
2. Kau, T .R.; Schroeder, F.; Ramaswamy, S.; Wojciechowski, C. L.; Zhao, J .J.; Roberts, T. M.; Clardy, J.; Sellers, W. R.; Silver, P. A. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell. 2003, 4, 463-476.
3. Comments in: Cancer Cell. 2003, 4, 419-420.
4. Tan, C.; de Noronha, R. G.; Roecker, A. J.; Pyrzynska, B.; Khwaja, F.; Zhang, Z.; Zhang, H.; Teng, Q.; Nicholson, A. C.; Giannakakou, P.; Zhou, W.; Olson, J. J.; Pereira, M. M.; Nicolaou, K. C.; VanMeir, E. G. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res. 2005, 65, 605-612.
5. Zegarra-Moro, O. L.; Schmidt, L. J.; Huang, H.; Tindall, D. J. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res. 2002, 62, 1008-1013.
6. Carbone, G. M.; Napoli, S.; Valentini, A.; Cavalli, F.; Watson, D. K.; Catapano, C. V. Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells. Nucleic Acids Res. 2004, 32, 4358-4367.
7. Baron, V.; Duss, S.; Rhim, J.; Mercola, D. Antisense to the early growth response-1 gene (Egr-1) inhibits prostate tumor development in TRAMP mice. Ann. N.Y. Acad. Sci. 2003, 1002, 197-216.
8. Tsuda, H.; Ohshima, Y.; Nomoto, H.; Fujita, K.; Matsuda, E.; Iigo, M.; Takasuka, N.; Moore, M. A. Cancer prevention by natural compounds. Drug Metab. Pharmacokinet. 2004, 19, 245-263.
9. Surh, Y. J. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 2003, 3, 768-780.
10. Klein, E. A. Chemoprevention of prostate cancer. Ann. Rev. Med. 2006, 57, 49-63.
11. Neill, M. G.; Fleshner, N. E. An update on chemoprevention strategies in prostate cancer for 2006. Curr. Opin. Urol. 2006, 16, 132-137.
12. Shand, R. L.; Gelmann, E. P. Molecular biology of prostate-cancer pathogenesis. Curr. Opin. Urol. 2006, 16, 123-131.
13. Edwards, J.; Krishna, N. S.; Witton, C. J.; Bartlett, J. M. Gene amplifications associated with the development of hormone-resistant prostate cancer. Clin. Cancer Res. 2003, 9, 5271-5281.
14. Jenster, G. The role of the androgen receptor in the development and progression of prostate cancer. Semin. Oncol. 1999, 26, 407-421.
15. Taplin, M. E.; Balk, S. P. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J. Cell Biochem. 2004, 91, 483-490.
16. Sadar, M. D. Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J. Biol. Chem. 1999, 274, 7777-7783.
17. Hobisch, A.; Eder, I. E.; Putz, T.; Horninger, W.; Bartsch, G.; Klocker, H.; Culig, Z. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. Cancer Res. 1998, 58, 4640-4645.
18. Ruizeveld de Winter, J. A.; Janssen, P. J.; Sleddens, H. M.; Verleun-Mooijman, M. C.; Trapman, J.; Brinkmann, A. O.; Santerse, A. B.; Schroder, F. H.; van der Kwast, T. H. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am. J. Pathol. 1994, 144, 735-746.
19. Helpap, B.; Kollermann, J. Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis. Virchows Arch. 1999, 434, 385-391.
20. Koivisto, P. A.; Helin, H. J. Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma. J. Pathol. 1999, 189, 219-223.
21. Latil, A.; Bieche, I.; Vidaud, D.; Lidereau, R.; Berthon, P.; Cussenot, O.; Vidaud, M. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res. 2001, 61, 1919-1926.
22. Kinoshita, H.; Shi, Y.; Sandefur, C.; Meisner, L. F.; Chang, C.; Choon, A.; Reznikoff, C. R.; Bova, G. S.; Friedl, A.; Jarrard, D. F. Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res. 2000, 60, 3623-3630.
23. Eder, I. E.; Culig, Z.; Ramoner, R.; Thurnher, M.; Putz, T.; Nessler-Menardi, C.; Tiefenthaler, M.; Bartsch, G.; Klocker, H. Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther. 2000, 7, 997-1007.
24. Zi, X.; Zhang, J.; Agarwal, R.; Pollak, M. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res. 2000, 60, 5617-5620.
25. Ren, F.; Zhang, S.; Mitchell, S. H.; Butler, R.; Young, C. Y. Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene, 2000, 19, 1924-1932.
26. Nakamura, K.; Yasunaga, Y.; Segawa, T.; Ko, D.; Moul, J. W.; Srivastava, S.; Rhim, J. S. Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int. J. Oncol. 2002, 21, 825-830.
27. Zhu, W.; Zhang, J. S.; Young, C. Y. Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis 2001, 22, 1399-1403.
28. Marks, L. S.; DiPaola, R. S.; Nelson, P.; Chen, S.; Heber, D.; Belldegrun, A. S.; Lowe, F. C.; Fan, J.; Leaders, F. E., Jr.; Pantuck, A. J.; Tyler, V. E. PC-SPES: herbal formulation for prostate cancer. Urology 2002, 60, 369-375; discussion 376-377.
29. Cha, T. L.; Qiu, L.; Chen, C. T.; Wen, Y.; Hung, M. C. Emodin down-regulates androgen receptor and inhibits prostate cancer cell growth. Cancer Res. 2005, 65, 2287-2295.
30. Jiang, C.; Lee, H. J.; Li, G. X.; Guo, J.; Malewicz, B.; Zhao, Y.; Lee, E. O.; Lee, H. J.; Lee, J. H.; Kim, M. S.; Kim, S. H.; Lu, J. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Cancer Res. 2006, 66, 453-463.
31. Bouwman, P.; Philipsen, S. Regulation of the activity of Sp1-related transcription factors. Mol. Cell. Endocrinol. 2002, 195, 27-38.
32. Suske, G. The Sp-family of transcription factors. Gene 1999, 238, 291-300.
33. Leggett, R. W.; Armstrong, S. A.; Barry, D.; Mueller, C. R. Sp1 is phosphorylated and its DNA binding activity down-regulated upon terminal differentiation of the liver. J. Biol. Chem. 1995, 270, 25879-25884.
34. Black, A. R.; Jensen, D.; Lin, S. Y.; Azizkhan, J. C. Growth/cell cycle regulation of Sp1 phosphorylation. J. Biol. Chem. 1999, 274, 1207-1215.
35. Saffer, J. D.; Jackson, S. P.; Annarella, M. B. Developmental expression of Sp1 in the mouse. Mol. Cell Biol. 1991, 11, 2189-2199.
36. Torigoe, T.; Izumi, H.; Yoshida, Y.; Ishiguchi, H.; Okamoto, T.; Itoh, H.; Kohno, K. Low pH enhances Sp1 DNA binding activity and interaction with TBP. Nucleic Acids Res. 2003, 31, 4523-4530.
37. Noe, V.; Alemany, C.; Nicolas, M.; Ciudad, C. J. Sp1 involvement in the 4beta-phorbol 12-myristate 13-acetate (TPA)-mediated increase in resistance to methotrexate in Chinese hamster ovary cells. Eur. J. Biochem. 2001, 268, 3163-3173.
38. Shin, T.; Sumiyoshi, H.; Matsuo, N.; Satoh, F.; Nomura, Y.; Mimata, H.; Yoshioka, H. Sp1 and Sp3 transcription factors upregulate the proximal promoter of the human prostate-specific antigen gene in prostate cancer cells. Arch. Biochem. Biophys. 2005, 435, 291-302.
39. Curtin, D.; Jenkins, S.; Farmer, N.; Anderson, A. C.; Haisenleder, D. J.; Rissman, E.; Wilson, E. M.; Shupnik, M. A. Androgen suppression of GnRH-stimulated rat LHbeta gene transcription occurs through Sp1 sites in the distal GnRH-responsive promoter region. Mol. Endocrinol. 2001, 15, 1906-1917.
40. Lu, S.; Jenster, G.; Epner, D. E. Androgen induction of cyclin-dependent kinase inhibitor p21 gene: role of androgen receptor and transcription factor Sp1 complex. Mol. Endocrinol. 2000, 14, 753-760.
41. Faber, P. W.; van Rooij, H. C.; Schipper, H. J.; Brinkmann, A. O.; Trapman, J. Two different, overlapping pathways of transcription initiation are active on the TATA-less human androgen receptor promoter. The role of Sp1. J. Biol. Chem. 1993, 268, 9296-9301.
42. Ren, F.; Zhang, S.; Mitchell, S. H.; Butler, R.; Young, C. Y. Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells. Oncogene 2000, 19, 1924-1932.
43. Yuan, H.; Gong, A.; Young, C. Y. Involvement of transcription factor Sp1 in quercetin-mediated inhibitory effect on the androgen receptor in human prostate cancer cells. Carcinogenesis 2005, 26, 793-801.
44. Sternberg, D. W.; Gilliland, D. G. The role of signal transducer and activator of transcription factors in leukemogenesis. J. Clin. Oncol. 2004, 22, 361-371.
45. Levy, D. E. Physiological significance of STAT proteins: investigations through gene disruption in vivo. Cell Mol. Life Sci. 1999, 55, 1559-1567.
46. Shuai, K.; Stark, G. R.; Kerr, I. M.; Darnell, J. E., Jr. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-gamma. Science 1993, 261, 1744-1746.
47. Schindler, U.; Hoey, T.; McKnight, S. L. Differentiation of T-helper lymphocytes: selective regulation by members of the STAT family of transcription factors. Genes Cells 1996, 1, 507-515.
48. Ihle, J. N.; Kerr, I. M. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet. 1995, 11, 69-74.
49. Leaman, D. W.; Pisharody, S.; Flickinger, T. W.; Commane, M. A.; Schlessinger, J.; Kerr, I. M.; Levy, D. E.; Stark, G. R. Roles of JAKs in activation of STATs and stimulation of c-fos gene expression by epidermal growth factor. Mol. Cell Biol. 1996, 16, 369-375.
50. Haura, E.B.; Turkson, J.; Jove, R. Mechanisms of disease: Insights into the emerging role of signal transducers and activators of transcription in cancer. Nat. Clin. Pract. Oncol. 2005, 2, 315-324.
51. Coffer, P. J.; Koenderman, L.; de Groot, R. P. The role of STATs in myeloid differentiation and leukemia. Oncogene 2000, 19, 2511-2522.
52. Grandis, J. R.; Drenning, S. D.; Zeng, Q.; Watkins, S. C.; Melhem, M. F.; Endo, S.; Johnson, D. E.; Huang, L.; He, Y.; Kim, J. D. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc. Natl. Acad. Sci. USA 2000, 97, 4227-4232.
53. Masuda, M.; Suzui, M.; Lim, J. T.; Deguchi, A.; Soh, J. W.; Weinstein, I. B. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J. Exp. Ther. Oncol. 2002, 2, 350-359.
54. Niu, G.; Wright, K. L.; Huang, M.; Song, L.; Haura, E.; Turkson, J.; Zhang, S.; Wang, T.; Sinibaldi, D.; Coppola, D.; Heller, R.; Ellis, L. M.; Karras, J.; Bromberg, J.; Pardoll, D.; Jove, R.; Yu, H. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002, 21, 2000-2008.
55. Sinibaldi, D.; Wharton, W.; Turkson, J.; Bowman, T.; Pledger, W. J.; Jove, R. Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene 2000, 19, 5419-5427.
56. Alas, S.; Bonavida, B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 2001, 61, 5137-5144.
57. Puthier, D.; Bataille, R.; Amiot, M. IL-6 up-regulates mcl-1 in human myeloma cells through JAK / STAT rather than ras / MAP kinase pathway. Eur. J. Immunol. 1999, 29, 3945-3950.
58. Aoki, Y.; Feldman, G. M.; Tosato, G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003, 101, 1535-1542.
59. Ni, Z.; Lou, W.; Leman, E. S.; Gao, A. C. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res. 2000, 60, 1225-1228.
60. Mora, L. B.; Buettner, R.; Seigne, J.; Diaz, J.; Ahmad, N.; Garcia, R.; Bowman, T.; Falcone, R.; Fairclough, R.; Cantor, A.; Muro-Cacho, C.; Livingston, S.; Karras, J.; Pow-Sang, J.; Jove, R. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002, 62, 6659-6666.
61. Barton, B. E.; Karras, J. G.; Murphy, T. F.; Barton, A.; Huang, H. F. Signal transducer and activator of transcription 3 (STAT3) activation in prostate cancer: Direct STAT3 inhibition induces apoptosis in prostate cancer lines. Mol. Cancer Ther. 2004, 3, 11-20.
62. Barton, B. E.; Murphy, T. F.; Adem, P.; Watson, R. A.; Irwin, R .J.; Huang, H. F. IL-6 signaling by STAT3 participates in the change from hyperplasia to neoplasia in NRP-152 and NRP-154 rat prostatic epithelial cells. BMC Cancer 2001, 1, 19.
63. Meydan, N.; Grunberger, T.; Dadi, H.; Shahar, M.; Arpaia, E.; Lapidot, Z.; Leeder, J. S.; Freedman, M.; Cohen, A.; Gazit, A.; Levitzki, A.; Roifman, C. M. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1996, 379, 645-648.
64. Blaskovich, M. A.; Sun, J.; Cantor, A.; Turkson, J.; Jove, R.; Sebti, S. M. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res. 2003, 63, 1270-1279.
65. Leong, P. L.; Andrews, G. A.; Johnson, D. E.; Dyer, K. F.; Xi, S.; Mai, J. C.; Robbins, P. D.; Gadiparthi, S.; Burke, N. A.; Watkins, S. F.; Grandis, J. R. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc. Natl. Acad. Sci. USA 2003, 100, 4138-4143.
66. Lee, S. O.; Lou, W.; Qureshi, K. M.; Mehraein-Ghomi, F.; Trump, D. L.; Gao, A. C. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 2004, 60, 303-309.
67. Nam, S.; Buettner, R.; Turkson, J.; Kim, D.; Cheng, J. Q.; Muehlbeyer, S.; Hippe, F.; Vatter, S.; Merz, K. H.; Eisenbrand, G.; Jove, R. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc. Natl. Acad. Sci. USA 2005, 102, 5998-6003.
68. Bemis, D. L.; Capodice, J. L.; Anastasiadis, A. G.; Katz, A. E.; Buttyan, R. Zyflamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression. Nutr. Cancer 2005, 52, 202-212.
69. Kotha, A.; Sekharam, M.; Cilenti, L.; Siddiquee, K.; Khaled, A.; Zervos, A. S.; Carter, B.; Turkson, J.; Jove, R. Resveratrol inhibits Src and Stat3 signaling and induces the apoptosis of malignant cells containing activated Stat3 protein. Mol. Cancer Ther. 2006, 5, 621-629.
70. Stanelle, J.; Putzer, B. M. E2F1-induced apoptosis: turning killers into therapeutics. Trends Mol. Med. 2006 Mar 8; [Epub ahead of print].
71. Stevaux, O.; Dyson, N. J. A revised picture of the E2F transcriptional network and RB function. Curr. Opin. Cell Biol. 2002, 14, 684-691.
72. Singh, R. P.; Agarwal, C.; Agarwal, R. Inositol hexaphosphate inhibits growth, and induces G1 arrest and apoptotic death of prostate carcinoma DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-E2F complexes. Carcinogenesis 2003, 24, 555-563.
73. Tyagi, A.; Agarwal, C.; Agarwal, R. Inhibition of retinoblastoma protein (Rb) phosphorylation at serine sites and an increase in Rb-E2F complex formation by silibinin in androgen-dependent human prostate carcinoma LNCaP cells: role in prostate cancer prevention. Mol. Cancer. Ther. 2002, 1, 525-532.
74. Tyagi, A.; Agarwal, C.; Agarwal, R. The cancer preventive flavonoid silibinin causes hypophosphorylation of Rb/p107 and Rb2/p130 via modulation of cell cycle regulators in human prostate carcinoma DU145 cells. Cell Cycle 2002, 1, 137-142.
75. Song, S. Y.; Lee, I.; Park, C.; Lee, H.; Hahm, J. C.; Kang, W. K. Neolignans from Saururus chinensis inhibit PC-3 prostate cancer cell growth via apoptosis and senescence-like mechanisms. Int. J. Mol. Med. 2005, 16, 517-523.
76. Lu, X.; Hsieh, T. C.; Wu, J. M. Equiguard suppresses androgen-dependent LNCaP prostate cancer cell proliferation by targeting cell cycle control via down regulation of the retinoblastoma protein Rb and induction of apoptosis via the release of cytochrome c. Int. J. Oncol. 2004, 25, 1801-1807.
77. Adams, P. D.; Kaelin, W. G., Jr. The cellular effects of E2F overexpression. Curr. Top Microbiol. Immunol. 1996, 208, 79-93.
78. Shan, B.; Lee, W. H. Deregulated expression of E2F-1 induces S-phase entry and leads to apoptosis. Mol. Cell Biol. 1994, 14, 8166-8173.
79. Wu, X.; Levine, A. J. p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci. USA 1994, 91, 3602-3606.
80. Holmberg, C.; Helin, K.; Sehested, M.; Karlstrom, O. E2F-1-induced p53-independent apoptosis in transgenic mice. Oncogene 1998, 17, 143-155.
81. Nguyen, K. H.; Hachem, P.; Khor, L. Y.; Salem, N.; Hunt, K. K.; Calkins, P. R.; Pollack, A. Adenoviral-E2F-1 radiosensitizes p53wild-type and p53null human prostate cancer cells. Int. J. Radiat. Oncol. Biol. Phys. 2005, 63, 238-246.
82. Perry, A. S.; Foley, R.; Woodson, K.; Lawler, M. The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr. Relat. Cancer 2006, 13, 357-377.
83. Patra, S. K.; Patra, A.; Zhao, H.; Dahiya, R. DNA methyltransferase and demethylase in human prostate cancer. Mol Carcinog. 2002, 33, 163-171.
84. Kimura, H.; Nakamura, T.; Ogawa, T.; Tanaka, S.; Shiota, K. Transcription of mouse DNA methyltransferase 1 (Dnmt1) is regulated by both E2F-Rb-HDAC-dependent and -independent pathways. Nucleic Acids Res. 2003, 31, 3101-3113.
85. McCabe, M. T.; Davis, J. N.; Day, M. L. Regulation of DNA methyltransferase 1 by the pRb/E2F1 pathway. Cancer Res. 2005, 65, 3624-3632.
86. McCabe, M. T.; Low, J. A.; Daignault, S.; Imperiale, M. J.; Wojno, K. J.; Day, M. L. Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res. 2006, 66, 385-392.
87. Fang M. Z, Wang, Y.; Ai, N.; Hou, Z.; Sun, Y.; Lu, H.; Welsh, W.; Yang, C. S. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003, 63, 7563-7570.
88. Varambally, S.; Dhanasekaran, S. M.; Zhou, M.; Barrette, T. R.; Kumar-Sinha, C.; Sanda, M. G.; Ghosh, D.; Pienta, K. J.; Sewalt, R. G.; Otte, A. P.; Rubin, M. A.; Chinnaiyan, A. M. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002, 419, 624-629.
89. Saramaki, O. R.; Tammela, T. L.; Martikainen, P. M.; Vessella, R. L.; Visakorpi, T. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer. 2006, 45, 639-645.
90. Silverman, E. S.; Collins, T. Pathways of Egr-1-mediated gene transcription in vascular biology. Am. J. Pathol. 1999, 154, 665-670.
91. Liu, C.; Rangnekar, V. M.; Adamson, E.; Mercola, D. Suppression of growth and transformation and induction of apoptosis by EGR-1. Cancer Gene Ther. 1998, 5, 3-28.
92. Sells, S. F.; Muthukumar, S.; Sukhatme, V. P.; Crist, S. A.; Rangnekar, V. M. The zinc finger transcription factor EGR-1 impedes interleukin-1-inducible tumor growth arrest. Mol. Cell Biol. 1995, 15, 682-692.
93. Eid, M. A.; Kumar, M. V.; Iczkowski, K. A.; Bostwick, D. G.; Tindall, D. J. Expression of early growth response genes in human prostate cancer. Cancer Res. 1998, 58, 2461-2468.
94. Abdulkadir, S. A. Mechanisms of prostate tumorigenesis: roles for transcription factors Nkx3.1 and Egr1. Ann. N.Y. Acad. Sci. 2005, 1059, 33-40.
95. Liu, C.; Calogero, A.; Ragona, G.; Adamson, E.; Mercola, D. EGR-1, the reluctant suppression factor: EGR-1 is known to function in the regulation of growth, differentiation, and also has significant tumor suppressor activity and a mechanism involving the induction of TGF-beta1 is postulated to account for this suppressor activity. Crit. Rev. Oncog. 1996, 7, 101-125.
96. Svaren, J.; Ehrig, T.; Abdulkadir, S. A.; Ehrengruber, M. U.; Watson, M. A.; Milbrandt, J. EGR1 target genes in prostate carcinoma cells identified by microarray analysis. J. Biol. Chem. 2000, 275, 38524-38531.
97. Virolle, T.; Krones-Herzig, A.; Baron, V.; De Gregorio, G.; Adamson, E. D.; Mercola, D. Egr1 promotes growth and survival of prostate cancer cells. Identification of novel Egr1 target genes. J. Biol. Chem. 2003, 278, 11802-11810.
98. Bello-Fernandez, C.; Cleveland, J. L. c-myc transactivates the ornithine decarboxylase gene. Curr. Top. Microbiol. Immunol. 1992, 182, 445-452.
99. Hermeking, H.; Rago, C.; Schuhmacher, M.; Li, Q.; Barrett, J. F.; Obaya, A. J.; O'Connell, B. C.; Mateyak, M. K.; Tam, W.; Kohlhuber, F.; Dang, C. V.; Sedivy, J. M.; Eick, D.; Vogelstein, B.; Kinzler, K. W. Identification of CDK4 as a target of c-MYC. Proc. Natl. Acad. Sci. USA 2000, 97, 2229-2234.
100. Luscher, B.; Eisenman, R. N. New light on Myc and Myb. Part I. Myc. Genes Dev. 1990, 4, 2025-2035.
101. Spencer, C. A.; Groudine, M. Control of c-myc regulation in normal and neoplastic cells. Adv. Cancer Res. 1991, 56, 1-48.
102. Nupponen, N. N.; Kakkola, L.; Koivisto, P.; Visakorpi, T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am. J. Pathol. 1998, 153, 141-148.
103. Prochownik, E. V.; Eagle Grove, L.; Deubler, D.; Zhu, X. L.; Stephenson, R. A.; Rohr, L. R.; Yin, X.; Brothman, A. R. Commonly occurring loss and mutation of the MXI1 gene in prostate cancer. Genes Chromosomes Cancer 1998, 22, 295-304.
104. Gil, J.; Kerai, P.; Lleonart, M.; Bernard, D.; Cigudosa, J. C.; Peters, G.; Carnero, A.; Beach, D. Immortalization of primary human prostate epithelial cells by c-Myc. Cancer Res. 2005, 65, 2179-2185.
105. Bernard, D.; Pourtier-Manzanedo, A.; Gil, J.; Beach, D. H. Myc confers androgen-independent prostate cancer cell growth. J. Clin. Invest. 2003, 112, 1724-1731.
106. Jagadeesh, S.; Kyo, S.; Banerjee, P. P. Genistein represses telomerase activity via both transcriptional and posttranslational mechanisms in human prostate cancer cells. Cancer Res. 2006, 66, 2107-2115.
107. Wu, K. J.; Grandori, C.; Amacker, M.; Simon-Vermot, N.; Polack, A.; Lingner, J.; Dalla-Favera, R. Direct activation of TERT transcription by c-MYC. Nat. Genet. 1999, 21, 220-224.
108. Wang, J.; Xie, L. Y.; Allan, S.; Beach, D.; Hannon, G. J. Myc activates telomerase. Genes Dev. 1998, 12, 1769-1774.
109. Albrecht, M.; Jiang, W.; Kumi-Diaka, J.; Lansky, E. P.; Gommersall, L. M.; Patel, A.; Mansel, R. E.; Neeman, I.; Geldof, A. A.; Campbell, M. J. Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. J. Med. Food. 2004, 7, 274-283.
110. Berra, E.; Benizri, E.; Ginouves, A.; Volmat, V.; Roux, D.; Pouyssegur, J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. Embo. J. 2003, 22, 4082-4090.
111. Semenza, G. L. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 2002, 8, S62-S67.
112. Forsythe, J. A.; Jiang, B. H.; Iyer, N. V.; Agani, F.; Leung, S. W.; Koos, R. D.; Semenza, G. L. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. 1996, 16, 4604-4613.
113. Krishnamachary, B.; Berg-Dixon, S.; Kelly, B.; Agani, F.; Feldser, D.; Ferreira, G.; Iyer, N.; LaRusch, J.; Pak, B.; Taghavi, P.; Semenza, G. L. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res. 2003, 63, 1138-1143.
114. Gray, M. J.; Zhang, J.; Ellis, L. M.; Semenza, G. L.; Evans, D. B.; Watowich, S. S.; Gallick, G. E. HIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Srcdependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomas. Oncogene 2005, 24, 3110-3120.
115. Zhong, H.; Agani, F.; Baccala, A. A.; Laughner, E.; Rioseco-Camacho, N.; Isaacs, W. B.; Simons, J. W.; Semenza, G. L. Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res. 1998, 58, 5280-5284.
116. Saramaki, O. R.; Savinainen, K. J.; Nupponen, N. N.; Bratt, O.; Visakorpi, T. Amplification of hypoxia-inducible factor 1alpha gene in prostate cancer. Cancer Genet. Cytogenet. 2001, 128, 31-34.
117. Du, Z.; Fujiyama, C.; Chen, Y.; Masaki Z. Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue. Chin. Med. J. (Engl). 2003, 116, 1936-1939.
118. Zhong, H.; Semenza, G. L.; Simons, J. W.; De Marzo, A. M. Upregulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect. Prev. 2004, 28, 88-93.
119. Fu, X. S.; Choi, E.; Bubley, G. J.; Balk, S. P. Identification of hypoxiainducible factor-1alpha (HIF-1alpha) polymorphism as a mutation in prostate cancer that prevents normoxia-induced degradation. Prostate 2005, 63, 215-221.
120. Chau, C. H.; Permenter, M. G.; Steinberg, S. M.; Retter, A. S.; Dahut, W. L.; Price, D. K.; Figg, W. D. Polymorphism in the hypoxia-inducible factor 1alpha gene may confer susceptibility to androgen-independent prostate cancer. Cancer Biol. Ther. 2005, 4, 1222-1225.
121. Tan, C.; de Noronha, R. G.; Roecker, A. J.; Pyrzynska, B.; Khwaja, F.; Zhang, Z.; Zhang, H.; Teng, Q.; Nicholson, A. C.; Giannakakou, P.; Zhou, W.; Olson, J. J.; Pereira, M. M.; Nicolaou, K. C.; Van Meir, E. G. Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway. Cancer Res. 2005, 65, 605-612.
122. Kung, A. L.; Zabludoff, S. D.; France, D. S.; Freedman, S. J.; Tanner, E. A.; Vieira, A.; Cornell-Kennon, S.; Lee, J.; Wang, B.; Wang, J.; Memmert, K.; Naegeli, H. U.; Petersen, F.; Eck, M. J.; Bair, K. W.; Wood, A. W.; Livingston, D. M. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 2004, 6, 33-43.
123. Hodges, T. W.; Hossain, C. F.; Kim, Y. P.; Zhou, Y. D.; Nagle, D. G. Molecular-targeted antitumor agents: the Saururus cernuus dineolignans manassantin B and 4-O-demethylmanassantin B are potent inhibitors of hypoxia-activated HIF-1. J. Nat. Prod. 2004, 67, 767-771.
124. Pikarsky, E.; Ben-Neriah, Y. NF-kappaB inhibition: a double-edged sword in cancer? Eur. J. Cancer 2006, 42, 779-784.
125. Greten, F. R.; Karin, M. The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett. 2004, 206, 193-199.
126. Hayden, M. S.; Ghosh, S. Signaling to NF-kappaB. Genes Dev. 2004, 18, 2195-2224.
127. Suh, J.; Rabson, A. B. NF-kappaB activation in human prostate cancer: important mediator or epiphenomenon? J. Cell. Biochem. 2004, 91, 100-117.
128. Dolcet, X.; Llobet, D.; Pallares, J.; Matias-Guiu, X. NF-kB in development and progression of human cancer. Virchows Arch. 2005, 446, 475-482.
129. Thakur, S.; Lin, H. C.; Tseng, W. T.; Kumar, S.; Bravo, R.; Foss, F.; Gelinas, C.; Rabson, A. B. Rearrangement and altered expression of the NFKB-2 gene in human cutaneous T-lymphoma cells. Oncogene 1994, 9, 2335-2344.
130. Neri, A.; Fracchiolla, N. S.; Migliazza, A.; Trecca, D.; Lombardi, L. The involvement of the candidate proto-oncogene NFKB2/lyt-10 in lymphoid malignancies. Leuk. Lymphoma 1996, 23, 43-48.
131. Cabannes, E.; Khan, G.; Aillet, F.; Jarrett, R. F.; Hay, R. T. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaB alpha. Oncogene 1999, 18, 3063-3070.
132. Ondrey, F. G.; Dong, G.; Sunwoo, J.; Chen, Z.; Wolf, J. S.; Crowl-Bancroft, C. V.; Mukaida, N.; Van Waes, C. Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express pro-inflammatory and pro-angiogenic cytokines. Mol. Carcinog. 1999, 26, 119-129.
133. Wang, W.; Abbruzzese, J. L.; Evans, D. B.; Chiao, P. J. Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene 1999, 18, 4554-4563.
134. Shattuck-Brandt, R. L.; Richmond, A. Enhanced degradation of I-kappaB alpha contributes to endogenous activation of NF-kappaB in Hs294T melanoma cells. Cancer Res. 1997, 57, 3032-3039.
135. Nakshatri, H.; Bhat-Nakshatri, P.; Martin, D. A.; Goulet, R. J., Jr.; Sledge, G. W., Jr. Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol. Cell Biol. 1997, 17, 3629-3639.
136. Dhawan, P.; Singh, A. B.; Ellis, D. L.; Richmond, A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res. 2002, 62, 7335-7342.
137. Tai, D. I.; Tsai, S. L.; Chang, Y. H.; Huang, S. N.; Chen, T. C.; Chang, K. S.; Liaw, Y. F. Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma. Cancer 2000, 89, 2274-2281.
138. Ludwig, L.; Kessler, H.; Wagner, M.; Hoang-Vu, C.; Dralle, H.; Adler, G.; Bohm, B. O.; Schmid, R. M. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Res. 2001, 61, 4526-4535.
139. Palayoor, S. T.; Youmell, M. Y.; Calderwood, S. K.; Coleman, C. N.; Price, B. D. Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999, 18, 7389-7394.
140. Huang, S.; Pettaway, C. A.; Uehara, H.; Bucana, C. D.; Fidler, I. J. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001, 20, 4188-4197.
141. Gasparian, A. V.; Yao, Y. J.; Kowalczyk, D.; Lyakh, L. A.; Karseladze, A.; Slaga, T. J.; Budunova, I. V. The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J. Cell Sci. 2002, 115, 141-151.
142. Chen, C. D.; Sawyers, C. L. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol. Cell Biol. 2002, 22, 2862-2870.
143. Coffey, R. N.; Watson, R. W.; O'Neill, A. J.; Mc Eleny, K.; Fitzpatrick, J. M. Androgen-mediated resistance to apoptosis. Prostate 2002, 53, 300-309.
144. Ripple, M. O.; Henry, W. F.; Schwarze, S. R.; Wilding, G.; Weindruch, R. Effect of antioxidants on androgen-induced AP-1 and NF-kappaB DNA-binding activity in prostate carcinoma cells. J. Natl. Cancer Inst. 1999, 91, 1227-1232.
145. Lessard, L.; Mes-Masson, A. M.; Lamarre, L.; Wall, L.; Lattouf, J. B.; Saad, F. NF-kappa B nuclear localization and its prognostic significance in prostate cancer. BJU Int. 2003, 91, 417-420.
146. Lessard, L.; Begin, L. R.; Gleave, M. E.; Mes-Masson, A. M.; Saad, F. Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study. Br. J. Cancer 2005, 93, 1019-1023.
147. Ismail, H. A.; Lessard, L.; Mes-Masson, A. M.; Saad, F. Expression of NF-kappaB in prostate cancer lymph node metastases. Prostate 2004, 58, 308-313.
148. Fradet, V.; Lessard, L.; Begin, L. R.; Karakiewicz, P.; Masson, A. M.; Saad, F. Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin. Cancer Res. 2004, 10, 8460-8464.
149. Chinni, S. R.; Li, Y.; Upadhyay, S.; Koppolu, P. K.; Sarkar, F. H. Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. Oncogene 2001, 20, 2927-2936.
150. Shukla, S.; Gupta, S. Molecular mechanisms for apigenin-induced cell-cycle arrest and apoptosis of hormone refractory human prostate carcinoma DU145 cells. Mol. Carcinog. 2004, 39, 114-126.
151. Shukla, S.; Gupta, S. Suppression of constitutive and tumor necrosis factor alpha-induced nuclear factor (NF)-kappaB activation and induction of apoptosis by apigenin in human prostate carcinoma PC-3 cells: correlation with down-regulation of NF-kappaB-responsive genes. Clin. Cancer Res. 2004, 10, 3169-3178.
152. Xu, C.; Shen, G.; Chen, C.; Gelinas, C.; Kong, A. N. Suppression of NF-kappaB and NF-kappaB-regulated gene expression by sulforaphane and PEITC through IkappaBalpha, IKK pathway in human prostate cancer PC-3 cells. Oncogene 2005, 24, 4486-4495.
153. Deeb, D. D.; Jiang, H.; Gao, X.; Divine, G.; Dulchavsky, S. A.; Gautam, S. C. Chemosensitization of hormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis. J. Exp. Ther. Oncol. 2005, 5, 81-91.
154. Khor, T. O.; Keum, Y. S.; Lin, W.; Kim, J. H.; Hu, R.; Shen, G.; Xu, C.; Gopalakrishnan, A.; Reddy, B.; Zheng, X.; Conney, A. H.; Kong, A. N. Combined inhibitory effects of curcumin and phenethyl isothiocyanate on the growth of human PC-3 prostate xenografts in immunodeficient mice. Cancer Res.
155. Sliva, D.; Labarrere, C.; Slivova, V.; Sedlak, M.; Lloyd, F. P., Jr.; Ho, N. W. Ganoderma lucidum suppresses motility of highly invasive breast and prostate cancer cells. Biochem. Biophys. Res. Commun. 2002, 298, 603-612.
156. Sliva, D.; Sedlak, M.; Slivova, V.; Valachovicova, T.; Lloyd, F. P., Jr.; Ho, N. W. Biologic activity of spores and dried powder from Ganoderma lucidum for the inhibition of highly invasive human breast and prostate cancer cells. J. Altern. Complement. Med. 2003, 9, 491-497.
157. Dhanalakshmi, S.; Singh, R. P.; Agarwal, C.; Agarwal, R. Silibinin inhibits constitutive and TNFalpha-induced activation of NF-kappaB and sensitizes human prostate carcinoma DU145 cells to TNFalpha-induced apoptosis. Oncogene 2002, 21, 1759-1767.
158. Agarwal, C.; Dhanalakshmi, S.; Singh, R. P.; Agarwal, R. Inositol hexaphosphate inhibits constitutive activation of NF- kappa B in androgen-independent human prostate carcinoma DU145 cells. Anticancer Res. 2003, 23, 3855-3861.
159. Bode, A. M.; Dong, Z. Signal transduction pathways: targets for chemoprevention of skin cancer. Lancet Oncol. 2000, 1, 181-188.
160. Bernstein, L. R.; Colburn, N. H. AP-1/jun function is differentially induced in promotion-sensitive and resistant JB6 cells. Science 1989, 244, 566-569.
161. Shaulian, E.; Karin, M. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 2002, 4, E131-E136.
162. Chen, F.; Ma, L.; Al-Ansari, N.; Shneider, B. The role of AP-1 in the transcriptional regulation of the rat apical sodium-dependent bile acid transporter. J. Biol. Chem. 2001, 276, 38703-38714.
163. Shaulian, E.; Karin, M. AP-1 in cell proliferation and survival. Oncogene 2001, 20, 2390-2400.
164. Feng, R.; Lu, Y.; Bowman, L. L.; Qian, Y.; Castranova, V.; Ding, M. Inhibition of activator protein-1, NF-kappaB, and MAPKs and induction of phase 2 detoxifying enzyme activity by chlorogenic acid. J. Biol. Chem. 2005, 280, 27888-27895.
165. Feng, R.; Bowman, L. L.; Lu, Y.; Leonard, S. S.; Shi, X.; Jiang, B. H.; Castranova, V.; Vallyathan, V.; Ding, M. Blackberry extracts inhibit activating protein 1 activation and cell transformation by perturbing the mitogenic signaling pathway. Nutr. Cancer 2004, 50, 80-89.
166. Yu, R.; Hebbar, V.; Kim, D. W.; Mandlekar, S.; Pezzuto, J. M.; Kong, A. N. Resveratrol inhibits phorbol ester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways. Mol. Pharmacol. 2001, 60, 217-224.
167. Mukhopadhyay, A.; Bueso-Ramos, C.; Chatterjee, D.; Pantazis, P.; Aggarwal, B. B. Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 2001, 20, 7597-7609.
168. Nakamura, K.; Yasunaga, Y.; Segawa, T.; Ko, D.; Moul, J. W.; Srivastava, S.; Rhim, J. S. Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int. J. Oncol. 2002, 21, 825-830.
169. Tyagi, A.; Agarwal, R.; Agarwal, C. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis. Oncogene 2003, 22, 1302-1316.
170. Sliva, D.; Sedlak, M.; Slivova, V.; Valachovicova, T.; Lloyd, F. P., Jr.; Ho, N. W. Biologic activity of spores and dried powder from Ganoderma lucidum for the inhibition of highly invasive human breast and prostate cancer cells. J. Altern. Complement. Med. 2003, 9, 491-497.
171. Xu, C.; Shen, G.; Yuan, X.; Kim, J. H.; Gopalkrishnan, A.; Keum, Y. S.; Nair, S.; Kong, A. N. ERK and JNK signaling pathways are involved in the regulation of activator protein 1 and cell death elicited by three isothiocyanates in human prostate cancer PC-3 cells. Carcinogenesis 2006, 27, 437-445.
172. Crepieux, P.; Coll, J.; Stehelin, D. The Ets family of proteins: weak modulators of gene expression in quest for transcriptional partners. Crit. Rev. Oncog. 1994, 5, 615-638.
173. Scott, E. W.; Simon, M. C.; Anastasi, J.; Singh, H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. Science 1994, 265, 1573-1577.
174. Langer, S. J.; Bortner, D. M.; Roussel, M. F.; Sherr, C. J.; Ostrowski, M. C. Mitogenic signaling by colony-stimulating factor 1 and ras is suppressed by the ets-2 DNA-binding domain and restored by myc overexpression. Mol. Cell Biol. 1992, 12, 5355-5362.
175. Galang, C. K.; Garcia-Ramirez, J.; Solski, P. A.; Westwick, J. K.; Der, C. J.; Neznanov, N. N.; Oshima, R. G.; Hauser, C. A. Oncogenic Neu/ErbB-2 increases ets, AP-1, and NF-kappaB-dependent gene expression, and inhibiting ets activation blocks Neu-mediated cellular transformation. J. Biol. Chem. 1996, 271, 7992-7998.
176. Bassuk, A. G.; Leiden, J. M. A direct physical association between ETS and AP-1 transcription factors in normal human T cells. Immunity 1995, 3, 223-237.
177. Buttice, G.; Duterque-Coquillaud, M.; Basuyaux, J. P.; Carrere, S.; Kurkinen, M.; Stehelin, D. Erg, an Ets-family member, differentially regulates human collagenase1 (MMP1) and stromelysin1 (MMP3) gene expression by physically interacting with the Fos/Jun complex. Oncogene 1996, 13, 2297-2306.
178. Basuyaux, J. P.; Ferreira, E.; Stehelin, D.; Buttice, G. The Ets transcription factors interact with each other and with the c-Fos/c-Jun complex via distinct protein domains in a DNA-dependent and -independent manner. J. Biol. Chem. 1997, 272, 26188-26195.
179. Carrere, S.; Verger, A.; Flourens, A.; Stehelin, D.; Duterque-Coquillaud, M. Erg proteins, transcription factors of the Ets family, form homo, heterodimers and ternary complexes via two distinct domains. Oncogene 1998, 16, 3261-3268.
180. Liu, A. Y.; Corey, E.; Vessella, R. L.; Lange, P. H.; True, L. D.; Huang, G. M.; Nelson, P. S.; Hood, L. Identification of differentially expressed prostate genes: increased expression of transcription factor ETS-2 in prostate cancer. Prostate 1997, 30, 145-153.
181. Sementchenko, V. I.; Schweinfest, C. W.; Papas, T. S.; Watson, D. K. ETS2 function is required to maintain the transformed state of human prostate cancer cells. Oncogene 1998, 17, 2883-2888.
182. Foos, G.; Garcia-Ramirez, J. J.; Galang, C. K.; Hauser, C. A. Elevated expression of Ets2 or distinct portions of Ets2 can reverse Ras-mediated cellular transformation. J. Biol. Chem. 1998, 273, 18871-18880.
183. Carbone, G. M.; McGuffie, E.; Napoli, S.; Flanagan, C. E.; Dembech, C.; Negri, U.; Arcamone, F.; Capobianco, M. L.; Catapano, C. V. DNA binding and antigene activity of a daunomycin-conjugated triplex-forming oligonucleotide targeting the P2 promoter of the human c-myc gene. Nucleic Acids Res. 2004, 32, 2396-2410.
184. Liu, A. Y.; Corey, E.; Vessella, R. L.; Lange, P. H.; True, L. D.; Huang, G. M.; Nelson, P. S.; Hood, L. Identification of differentially expressed prostate genes: increased expression of transcription factor ETS-2 in prostate cancer. Prostate 1997, 30, 145-153.
185. Gavrilov, D.; Kenzior, O.; Evans, M.; Calaluce, R.; Folk, W. R. Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers. Eur. J. Cancer 2001, 37, 1033-1040.
186. Yoon, J. W.; Kita, Y.; Frank, D. J.; Majewski, R. R.; Konicek, B. A.; Nobrega, M. A.; Jacob, H.; Walterhouse, D.; Iannaccone, P. Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. J. Biol. Chem. 2002, 277, 5548-5555.
187. Ingham, P. W.; McMahon, A. P. Hedgehog signaling in animal development: paradigms and principles. Genes Dev. 2001, 15, 3059-3087.
188. Taipale, J.; Beachy, P. A. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001, 411, 349-354.
189. Litingtung, Y.; Lei, L.; Westphal, H.; Chiang, C. Sonic hedgehog is essential to foregut development. Nat. Genet. 1998, 20, 58-61.
190. Podlasek, C. A.; Barnett, D. H.; Clemens, J. Q.; Bak, P. M.; Bushman, W. Prostate development requires Sonic hedgehog expressed by the urogenital sinus epithelium. Dev. Biol. 1999, 209, 28-39.
191. Berman, D. M.; Karhadkar, S. S.; Maitra, A.; Montes De Oca, R.; Gerstenblith, M. R.; Briggs, K.; Parker, A. R.; Shimada, Y.; Eshleman, J. R.; Watkins, D. N.; Beachy, P. A. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003, 425, 846-851.
192. Thayer, S. P.; di Magliano, M. P.; Heiser, P. W.; Nielsen, C. M.; Roberts, D. J.; Lauwers, G. Y.; Qi, Y. P.; Gysin, S.; Fernandez-del Castillo, C.; Yajnik, V.; Antoniu, B.; McMahon, M.; Warshaw, A. L.; Hebrok, M. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003, 425, 851-856.
193. Watkins, D. N.; Berman, D. M.; Burkholder, S. G.; Wang, B.; Beachy, P. A.; Baylin, S. B. Hedgehog signalling within airway epithelial progenitors and in small-cell lung cancer. Nature 2003, 422, 313-317.
194. Sanchez, P.; Hernandez, A. M.; Stecca, B.; Kahler, A. J.; DeGueme, A. M.; Barrett, A.; Beyna, M.; Datta, M. W.; Datta, S.; Ruiz i Altaba, A. Inhibition of prostate cancer proliferation by interference with SONIC HEDGEHOG-GLI1 signaling. Proc. Natl. Acad. Sci. USA 2004, 101, 12561-12566.
195. Karhadkar, S. S.; Bova, G. S.; Abdallah, N.; Dhara, S.; Gardner, D.; Maitra, A.; Isaacs, J. T.; Berman, D. M.; Beachy, P. A. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 2004, 431, 707-712.
196. Sheng, T.; Li, C.; Zhang, X.; Chi, S.; He, N.; Chen, K.; McCormick, F.; Gatalica, Z.; Xie, J. Activation of the hedgehog pathway in advanced prostate cancer. Mol. Cancer 2004, 3, 29.
197. Vogelstein, B.; Lane, D.; Levine, A. J. Surfing the p53 network. Nature 2000, 408, 307-310.
198. Vousden, K. H.; Lu, X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2002, 2, 594-604.
199. Jin, S.; Levine, A. J. The p53 functional circuit. J. Cell Sci. 2001, 114, 4139-4140.
200. Giaccia, A. J.; Kastan, M. B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 1998, 12, 2973-2983.
201. Gudkov, A. V.; Komarova, E. A. The role of p53 in determining sensitivity to radiotherapy. Nat. Rev. Cancer 2003, 3, 117-129.
202. Appella, E.; Anderson, C. W. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 2001, 268, 2764-2772.
203. Colman, M. S.; Afshari, C. A.; Barrett, J. C. Regulation of p53 stability and activity in response to genotoxic stress. Mutat. Res. 2000, 462, 179-188.
204. Nakamura, Y. Isolation of p53-target genes and their functional analysis. Cancer Sci. 2004, 95, 7-11.
205. Miyashita, T.; Reed, J. C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995, 80, 293-299.
206. Yu, J.; Zhang, L.; Hwang, P. M.; Kinzler, K. W.; Vogelstein, B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 2001, 7, 673-682.
207. Nakano, K.; Vousden, K. H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 2001, 7, 683-694.
208. Han, J.; Flemington, C.; Houghton, A. B.; Gu, Z.; Zambetti, G. P.; Lutz, R. J.; Zhu, L.; Chittenden, T. Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals. Proc. Natl. Acad. Sci. USA 2001, 98, 11318-11323.
209. Oda, E.; Ohki, R.; Murasawa, H.; Nemoto, J.; Shibue, T.; Yamashita, T.; Tokino, T.; Taniguchi, T.; Tanaka, N. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288, 1053-1058.
210. Sheikh, M. S.; Burns, T. F.; Huang, Y.; Wu, G. S.; Amundson, S.; Brooks, K. S.; Fornace, A. J., Jr.; el-Deiry, W. S. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res. 1998, 58, 1593-1598.
211. Liu, X.; Yue, P.; Khuri, F. R.; Sun, S. Y. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res. 2004, 64, 5078-5083.
212. Muller, M.; Wilder, S.; Bannasch, D.; Israeli, D.; Lehlbach, K.; Li-Weber, M.; Friedman, S. L.; Galle, P. R.; Stremmel, W.; Oren, M.; Krammer, P. H. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 1998, 188, 2033-2045.
213. Yu, J.; Zhang, L. The transcriptional targets of p53 in apoptosis control. Biochem. Biophys. Res. Commun. 2005, 331, 851-858.
214. Symonds, H.; Krall, L.; Remington, L.; Saenz Robles, M.; Jacks, T.; Van Dyke, T. p53-dependent apoptosis in vivo: impact of p53 inactivation on tumorigenesis. Cold Spring Harb. Symp. Quant. Biol. 1994, 59, 247-257.
215. Liu, G.; Parant, J. M.; Lang, G.; Chau, P.; Chavez-Reyes, A.; El-Naggar, A. K.; Multani, A.; Chang, S.; Lozano, G. Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat. Genet. 2004, 36, 63-68.
216. Hussain, S. P.; Harris, C. C. p53 mutation spectrum and load: the generation of hypotheses linking the exposure of endogenous or exogenous carcinogens to human cancer. Mutat. Res. 1999, 428, 23-32.
217. Hastak, K.; Gupta, S.; Ahmad, N.; Agarwal, M. K.; Agarwal, M. L.; Mukhtar, H. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 2003, 22, 4851-4859.
218. Chen, S.; Gao, J.; Halicka, H. D.; Huang, X.; Traganos, F.; Darzynkiewicz, Z. The cytostatic and cytotoxic effects of oridonin (Rubescenin), a diterpenoid from Rabdosia rubescens, on tumor cells of different lineage. Int. J. Oncol. 2005, 26, 579-588.
219. Shih, A.; Zhang, S.; Cao, H. J.; Boswell, S.; Wu, Y. H.; Tang, H. Y.; Lennartz, M. R.; Davis, F. B.; Davis, P. J.; Lin, H. Y. Inhibitory effect of epidermal growth factor on resveratrol-induced apoptosis in prostate cancer cells is mediated by protein kinase C-alpha. Mol. Cancer Ther. 2004, 3, 13555-13564.
220. Narayanan, B. A.; Narayanan, N. K.; Re, G. G.; Nixon, D. W. Differential expression of genes induced by resveratrol in LNCaP cells: P53-mediated molecular targets. Int. J. Cancer 2003, 104, 204-212.